medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-4-54-59medsovet-2332Research ArticleОСЛОЖНЕНИЯ САХАРНОГО ДИАБЕТАCOMPLICATIONS OF DIABETESСтатины в лечении больных сахарным диабетом: место аторвастатинаStatines in treatment of patients with diabetes mellitus: niche of atorvastatineУразгильдееваС. А.UrazgildeevaS. A.

Доктор медицинских наук 

Научно-клинический и образовательный центр «Кардиология» медицинского факультета Санкт-Петербургского государственного университета; Центр атеросклероза и нарушений липидного обмена клинической больницы № 122 им. Л.Г. Соколова; Центр клинической липидологии Центра сердечной медицины «Черная Речка»

Санкт-Петербург

 

MD 

Cardiology Research Clinical and Educational Center of the Medical Faculty of St. Petersburg State University;

Sokolov Center for Atherosclerosis and Lipid Disorders in Clinical Hospital No. 122;

Center for Clinical Lipidology of Chernaya Rechka Center for Cardiac Medicine

St. Petersburg

Санкт-Петербургский государственный университет; Клиническая больница № 122 им. Л.Г. Соколова; Центр сердечной медицины «Черная Речка»РоссияSt. Petersburg State University; Clinical Hospital No. 122; Chernaya Rechka Center for Cardiac MedicineRussian Federation201831032018045459Copyright © Уразгильдеева С.А., 20182018Уразгильдеева С.А.Urazgildeeva S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2332

Обзор посвящен особенностям лечения статинами больных сахарным диабетом 2 типа с целью предотвращения серьезных сердечно-сосудистых осложнений.

The review is devoted to the features of statin therapy in patients with type 2 diabetes to prevent serious cardiovascular complications.

сахарный диабеткатегории рискадислипидемияцелевые уровни липидовгиполипидемическая терапиястатиныаторвастатинdiabetes mellitusrisk categoriesdyslipidemiatarget lipid levelslipid-lowering therapystatinsatorvastatinReferencesIDF Diabetes Atlas, 7th Edition, 2015. http://www.diabetesatlas.org/resources/2015-atlas.html.IDF Diabetes Atlas, 7th Edition, 2015. http://www.diabetesatlas.org/resources/2015-atlas.html.Алгоритмы специализированной медицинской помощи больным сахарным диабетом, 8-й выпуск, 2017. Под редакцией И.И. Дедова, М.В. Шестаковой. Сахарный диабет, 2017, 20(1S): 1-112Standards of specialized medical care in diabetes mellitus, 8th edition, 2017. Edited by Dedova II, Shestakova MV. Sakharniy Diabet, 2017, 20 (1S): 1-112.Yusuf S, Hawken S, Ounpuu S et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 coutries (the INTERHEART Study): case-control study. Lancet, 2004, 364(9438): 937-952.Yusuf S, Hawken S, Ounpuu S et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 coutries (the INTERHEART Study): case-control study. Lancet, 2004, 364(9438): 937-952.ESC/EAS Guidelenes for the Management of Dyslipidemias: The Task Force for the Management of Dyslipidemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Atherosclerosis, 2016, 253: 281-344.ESC/EAS Guidelenes for the Management of Dyslipidemias: The Task Force for the Management of Dyslipidemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Atherosclerosis, 2016, 253: 281-344.Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. VI пересмотр. Атеросклероз и дислипидемии, 2017, 3: 2-22.Diagnosis and correction of lipid metabolism disorders for the prevention and management of atherosclerosis. Russian guidelines VI revision. Ateroskleroz i Dislipidemii, 2017, 3: 2-22.Глинкина И.В. Лечение нарушений липидного обмена при сахарном диабете 2 типа. Лечащий врач, 2002, 6: 6-8.Glinkina IV. Treatment of lipid metabolism disorders in type 2 diabetes mellitus. Lechashchiy Vrach, 2002, 6: 6-8Sniderman AD, Lamarche B, Tilley J et al. Hypertriglyceridemic hyperapo B in type 2 diabetes. Diabetes Care, 2002, 25(3): 579-582.Sniderman AD, Lamarche B, Tilley J et al. Hypertriglyceridemic hyperapo B in type 2 diabetes. Diabetes Care, 2002, 25(3): 579-582.Уразгильдеева С.А., Малыгина О.Ф. Особенности лечения дислипидемии у больных сахарным диабетом 2-го типа. Медицинский совет, 2016, 3: 48–53.Features of dyslipidemia management in patients with type 2 diabetes mellitus. Meditsinskiy Sovet, 2016, 3: 48-53.Алексеева И.А., Сергиенко И.В. Роль аторвастатина во вторичной профилактике сердечно-сосудистых заболеваний в свете современных рекомендаций. Атеросклероз и дислипидемии, 2017, 3: 23-32.Alekseeva IA, Sergienko IV. The role of atorvastatin in the secondary prevention of cardiovascular diseases in the light of contemporary guidelines. Ateroskleroz i Dislipidemii, 2017, 3: 23-32Kwiterovich PO. Dyslipidemia in Special Groups. Dyslipidemia, 2010: 124.Kwiterovich PO. Dyslipidemia in Special Groups. Dyslipidemia, 2010: 124.Colhoun HM, Betteridge D.J., Durrington P.N. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004, 369: 685-696.Colhoun HM, Betteridge D.J., Durrington P.N. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004, 369: 685-696.Sever PS, Dahlöf B, Poulter NL et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet, 2003, 361: 1149-1158.Sever PS, Dahlöf B, Poulter NL et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet, 2003, 361: 1149-1158.Poulter NL, Sever PS, Dahlöf B et al. Role of blood pressure and other variables in the differential cardiovascular event noted in the -Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet, 2005, 366: 907-913.Poulter NL, Sever PS, Dahlöf B et al. Role of blood pressure and other variables in the differential cardiovascular event noted in the -Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet, 2005, 366: 907-913.Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care, 2006, 29: 1220-1226.Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care, 2006, 29: 1220-1226.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014, 129, 25(Suppl. 2): 1-45.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014, 129, 25(Suppl. 2): 1-45.Newman C, Tsai J, Szarek M et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Amer. J. Cardiol., 2006, 97(1): 61-67.Newman C, Tsai J, Szarek M et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Amer. J. Cardiol., 2006, 97(1): 61-67.De Zeeuw D., Anzalone DA, Cain VA et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol, 2015, 3: 181-190.De Zeeuw D., Anzalone DA, Cain VA et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol, 2015, 3: 181-190.Гуревич В.С., Уразгильдеева С.А., Шатилина Л.В. и др. Изменение уровней антител к окисленным липопротеидам при применении аторвастатина у женщин с ишемической болезнью сердца в постменопаузе. Кардиология, 2004, 44(4): 76-77.Gurevich VS, Urazgildeeva SA, Shatilina LV. Changes in the levels of antibodies to oxidized lipoproteins in the treatment of atorvastatin in women with coronary heart disease in postmenopausal women. Cardiologiya, 2004, 44 (4): 76-77.

The authors declare that there are no conflicts of interest present.